Ria Fitrah Arfiani, Dwi Hari Susilo, Budi Suprapti

Abstract views = 2809 times | downloads = 1714 times


Nausea and vomiting may occur in patients receiving chemotherapy, a condition referred to as chemotherapy-induced nausea and vomiting. The provision of combined dexamethasone and ondansetron or granisetron is the therapeutic management of acute phase nausea and vomiting in cytostatics with a high risk of nausea and vomiting. Granisetron has been known to have better pharmacokinetics and pharmacodynamics compared to ondansetron, so it is possible to have nausea and vomiting suppressing effect higher than that of ondansetron. This study aimed to compare antiemetic effectiveness of granisetron and dexamethasone with ondansetron and dexamethasone in acute-phase chemotherapy patients. This study was conducted in patients who received the combination of cisplatin-paclitaxel and cisplatin-fluorouracil, double-blind, with samples comprised new head and neck surgical oncology patients. Measurement of nausea and vomiting during the acute phase of chemotherapy was conducted using Index of Nausea, Vomiting, and Retching (INVR). Observation of nausea and vomiting in the patients was done during the first 12 hours after administration of cisplatin and interviews were conducted on h 12. Results showed that there was no difference in the effectiveness of nausea and vomiting suppression in the administration of granisetron and dexamethasone compared to ondanstron and dexamethasone in acute phase chemotherapy patients (p = 0.076).


granisetron; ondansetron; dexamethasone; acute phase; cisplatin; paclitaxel; fluorouracil

Full Text:



Aapro M (2004). Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist 9, 673-686

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH; American Society of Clinical Oncology (2011). Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29, 4189-4198

Brearley SG, Clements CV, Molassiotis A (2008). A review of patient self-report tools for chemotherapy-induced nausea and vomiting. Support Care Cancer 16, 1213-1229

Dempsey CL, Coop AJ, Shillington A, Farley PA, Eberhardt DR, O'Briant S (2004). Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. Am J Health Syst Pharm 61, 781-786

Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W, Friedman C (1998). Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 16, 1568-1573

Hesketh PJ (2008). Drug therapy chemotherapy-induced nausea and vomiting. N Engl J Med 358, 2482-2494

Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, Schmoll HJ (2007). A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 15, 1023-1033

Keyhanian S, Taziki O, Saravi MM, Fotokian Z (2009). A randomized comparison of granisetron plus dexamethason with granisetron alone for the control of acute chemotherapy-induced emesis and nausea. International Journal of Hematology-Oncology and Stem Cell Research 3, 27-30

Kim TH, Choi BM, Chin JH, Lee MS, Kim DH, Noh GJ (2007). The reliability and validity of the Rhodes Index of Nausea, Vomiting and Retching in postoperative nausea and vomiting. Korean J Anesthesiol 52, 59-65

Mahesh R, Perumal RV, Pandi PV (2004). Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Pharmazie 60, 83-96

Ministry of Health Republic of Indonesia (2010). Report on Result of National Basic Health Research (Riskesdas 2010), Jakarta, Departemen Kesehatan Republik Indonesia

Anonymous (1996). Rhodes index of nausea, vomiting and retching. Available from downloads/rhodes-index.pdf. Accessed January 12, 2016

Rojas C and Slusher BS (2012). Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 684, 1-7

Schnell F (2003). Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 8, 187-198

Italian Group for Antiemetic Research (1995). Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332, 1-5

Wood JM, Chapman K, Eilers J (2011). Tools for assessing nausea, vomiting, and retching. Cancer Nurs 34, E14-E24


  • There are currently no refbacks.

Copyright (c) 2017 Ria Fitrah Arfiani, Dwi Hari Susilo, Budi Suprapti

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Indexed By

View My Stats

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.